va vs da for newly diagnosed hig-risk aml

Conditions: Acute Myeloid Leukemia

Summary: this is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (aml) patients with adverse risk featuress. participants will be 1:1 randomly assigned to the va and da groups. once remission was achieved, consolidated chemotherapy will be performed and allogeneic hematopoietic stem cell transplantation is strongly recommended. after completion of the study intervention, participants will be followed-up every 1 to 2 months for up to 2 years.

this is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (aml) patients with adverse risk featuress. newly diagnosed aml patients with adverse risk features according to 2022 european leukemia net risk stratification will be enrolled. in the study, a novel second generation targeted sequencing panel for the fast screening of adverse mutations with 72-hours after the bone marrow samples will be utilized. randomized participants will receive induction treatment . participants will be 1:1 randomly assigned to the va and da groups. va regimen comprises of azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28. da regimen comprises of daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle. once remission was achieved, consolidated chemotherapy will be performed and allogeneic hematopoietic stem cell transplantation is strongly recommended. after completion of the study intervention, participants will be followed-up every 1 to 2 months for up to 2 years.

Eligibility criteria:
inclusion criteria: 1. gender: female or male. 2. age:18-64 years old. 3. patients with newly diagnosed aml according to the who 2022 classification. 4. aml patients with adverse risk features according to the 2022 european leukemia net risk stratification. 5. untreated aml (hydroxyurea, and low dose cytarabine with cummulative dose \<1.0g are permitted). 6. ecog: 0-2. 7. adequate liver function: total bilirubin ≤ 1.5×upper limit of normal (uln); aspartate aminotransferase (ast) ≤3×uln (liver infiltration of leukemia: ≤5×uln); alanine aminotransferase (alt)≤3×uln (liver infiltration of leukemia: ≤5×uln) . 8. adequate renal function: ccr (creatinine clearance rate) ≥30 ml/min. 9. be able to understand and be willing to participate in the study. be able to provide written informed consent. exclusion criteria: 1. patients with acute promyeloid leukemia. 2. aml with central nervous system infiltration. 3. patients diagnosed with myeloid sarcoma. 4. patients have aml secondary to mds and previously been treated with hypomethylating agents. 5. patients with active infection, which is considered as uncontrollable by the investigator. 6. patients with active hepatitis b, hepatitis c and hiv infection. 7. patients with heart failure (grade 3-4); 8. patients who are pregnant or breastfeeding. 9. patients who refused to be enrolled in the study. patients who are considered as ineligible for the enrollment by the investigators.

Keywords: adverse risk, newly diagnosed, induction therapy